COVID-19 VACINE MODERNA GUIDANCE FOR THE GENERAL PUBLICCOVID-19 VACINE MODERNA GUIDANCE FOR HEALTH CARE PROVIDERSCOVID-19 VACINE JANSSEN GUIDANCE FOR THE GENERAL PUBLICCOVID-19 VACINE JANSSEN GUIDANCE FOR HEALTH CARE PROVIDERSCOVID-19 VACINE GAMALEYA GUIDANCE FOR HEALTH CARE PROVIDERSCOVID-19 VACINE GAMALEYA GUIDANCE FOR THE GENERAL PUBLICCOVID-19 VACCINE SINOVAC GUIDANCE FOR HEALTH CARE PROVIDERSCOVID-19 VACCINE SINOVAC GUIDANCE FOR THE GENERAL PUBLICCOVID-19 VACCINE ASTRAZENECA GUIDANCE FOR PATIENTSPFIZER-BIONTECH COVID-19 VACCINE GUIDANCE FOR PATIENTSCOVID-19 VACCINE ASTRAZENECA GUIDANCE FOR HEALTH CARE PROVIDERSHTAC recommends COVID-19 Vaccine AstraZeneca under emergency use for reducing COVID-19 risk in persons aged 18 and olderPFIZER-BIONTECH COVID-19 VACCINE for health care providersHTAC recommends Pfizer-BioNTech COVID-19 Vaccine under emergency use for reducing COVID-19 risk in persons aged 16 and olderHTA Philippines publishes HTAC Evaluation Framework for COVID-19 VaccinesURGENT HIRINGHTAC recommends pooled RT-PCR testing to monitor COVID transmission in populations with low case numbersHTAC recommends Rapid Antigen Test kits for symptomatic COVID-19, contact tracing, managing outbreaks and supplementing lack of RT-PCR confirmatory testingStrengthening COVID-19 response in the Philippines through Health Technology Assessment: A webinar for Evidence-Based Health Care (EBHC) Day 2020.HTAC releases guidance for ECMO, notes insufficient evidence to recommend useHTA and the COVID-19 pandemicDOH Releases New Implementing Guidelines on HTA DOH holds first HTA public consultationDOH holds HTA Workshop and Policy SymposiumTowards UHC: DOH and PhilHealth gear up for HTADOH holds high-level forum to accelerate HTADOH convenes local experts to create HTAC EVENTS AND PRESS RELEASES HEALTH TECHNOLOGY ASSESSMENT 101: MOVING TOGETHER TOWARDS UNIVERSAL HEALTHCARE STRENGTHENING COVID-19 RESPONSE IN THE PHILIPPINES THROUGH HEALTH TECHNOLOGY ASSESSMENT: A WEBINAR FOR EVIDENCE-BASED HEALTH CARE (EBHC) DAY 2020 HTA and the COVID-19 pandemic DOH Releases New Implementing Guidelines on HTA DOH holds first HTA public consultation DOH holds HTA Wokshop and Policy Symposium READ MORE HTAC RECOMMENDATIONS Lapatinib in treatment of HER2-positive breast cancer patients Favipiravir (Avigan) AMTI uAI-Discover-PNA Meglumine Acridone Acetate (Cycloferon) Huawei Cloud AI-Assisted Diagnosis READ MORE FOR STAKEHOLDER CONSULTATION Preliminary Recommendation on Lapatinib Preliminary Recommendation on 0.1% Sodium Hyaluronate (15 mL) and 2.5% Peritoneal Dialysis Solution (2L and 5L) News briefs HTAC RECOMMENDS COVID-19 VACCINE MODERNA UNDER EMERGENCY USE FOR REDUCING COVID-19 RISK IN PERSONS AGED 18 AND OLDER HTAC RECOMMENDS COVID-19 VACCINE JANSSEN UNDER EMERGENCY USE FOR REDUCING COVID-19 RISK IN PERSONS AGED 18 AND OLDER HTAC RECOMMENDS GAMALEYA COVID-19 VACCINE SPUTNIK V UNDER EMERGENCY USE FOR REDUCING COVID-19 RISK IN PERSONS AGED 18 AND OLDER HTAC RECOMMENDS COVID-19 VACCINE SINOVAC UNDER EMERGENCY USE FOR REDUCING COVID-19 RISK IN PERSONS AGED 18 AND OLDER HTAC recommends COVID-19 Vaccine AstraZeneca under emergency use for reducing COVID-19 risk in persons aged 18 and older HTAC recommends Pfizer-BioNTech COVID-19 Vaccine under emergency use for reducing COVID-19 risk in persons aged 16 and older Posts navigation 12 Older Older CONTACT US Business Hours: 8:00 a.m. to 5:00 p.m. (GMT+8) | Monday to Friday Email: hta@doh.gov.ph Telephone: 8-875-7734 ext. 260 Address: 4th Floor, Philippine Blood Disease and Transfusion Center, Lung Center Compound, Quezon Avenue, Diliman, Quezon City
STRENGTHENING COVID-19 RESPONSE IN THE PHILIPPINES THROUGH HEALTH TECHNOLOGY ASSESSMENT: A WEBINAR FOR EVIDENCE-BASED HEALTH CARE (EBHC) DAY 2020
Preliminary Recommendation on 0.1% Sodium Hyaluronate (15 mL) and 2.5% Peritoneal Dialysis Solution (2L and 5L)
HTAC RECOMMENDS COVID-19 VACCINE MODERNA UNDER EMERGENCY USE FOR REDUCING COVID-19 RISK IN PERSONS AGED 18 AND OLDER
HTAC RECOMMENDS COVID-19 VACCINE JANSSEN UNDER EMERGENCY USE FOR REDUCING COVID-19 RISK IN PERSONS AGED 18 AND OLDER
HTAC RECOMMENDS GAMALEYA COVID-19 VACCINE SPUTNIK V UNDER EMERGENCY USE FOR REDUCING COVID-19 RISK IN PERSONS AGED 18 AND OLDER
HTAC RECOMMENDS COVID-19 VACCINE SINOVAC UNDER EMERGENCY USE FOR REDUCING COVID-19 RISK IN PERSONS AGED 18 AND OLDER
HTAC recommends COVID-19 Vaccine AstraZeneca under emergency use for reducing COVID-19 risk in persons aged 18 and older
HTAC recommends Pfizer-BioNTech COVID-19 Vaccine under emergency use for reducing COVID-19 risk in persons aged 16 and older